This case report suggests that dual antiplatelet therapy with clopidogrel and aspirin may be used successfully during pregnancy in high-risk patients with a recent drug-eluting stent, without causing fetal anomalies.
May guide individualized DAPT decisions in high-risk pregnant stent patients; leaves open the need for prospective safety data.
Management of ischemic heart disease in pregnant women is still difficult, as there is little experience with many of the newer treatments such as clopidogrel. The safety of clopidogrel in pregnancy is unknown, especially in combination with aspirin. Its use during gestation has been described in a few case reports. We describe the case of a 36-year-old woman in her 9th week of pregnancy with a history of chronic hypertension, dyslipidemia and CAD, who required antiplatelet treatment. Clopidogrel and aspirin were administrated until one week before delivery and a healthy child was born at 36 weeks of pregnancy by caesarean section, without any complication.
No takes yet. Share an insight, caveat, or question.
Santis et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: